AYTU — Aytu BioPharma, Inc.

Summary of Aytu BioPharma Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $13.9 million for Q1 2026, down from $16.6 million in Q1 2025. Excluding a one-time rebate benefit from the previous year, revenue increased by approximately 5%.
• ADHD Portfolio Revenue: $13.2 million, down from $15.3 million year-over-year. Adjusted for the rebate, this represents a 10% increase.
• Pediatric Portfolio Revenue: $0.7 million, down from $1.3 million, attributed to manufacturing delays and a strategic deemphasis on marketing.
• Gross Margin: 66%, compared to 72% in the prior year. Adjusted for the rebate, gross margin improved slightly from 65%.
• Operating Expenses: $10.2 million, down from $11.2 million, due to cost reductions and operational efficiencies, despite increased spending for EXXUA's launch.
• Net Income: $2 million ($0.21 per share), compared to $1.5 million ($0.24 per share) in the previous year.
• Adjusted EBITDA: Negative $0.6 million, down from positive $1.9 million in the prior year.

2. Strategic Updates and Business Highlights

• EXXUA Launch: On track for a launch by the end of calendar 2025, with significant preparations underway including sales force training, product positioning, and KOL engagement.
• RxConnect Platform: Approximately 85% of ADHD prescriptions are dispensed through this platform, which is expected to facilitate the EXXUA launch.
• Patent Extension: Aytu secured a patent extension for EXXUA until September 2030, enhancing its market exclusivity.
• ADHD Market Position: Despite the potential entry of generics, Aytu believes its ADHD portfolio will maintain market share due to its unique RxConnect platform and the introduction of its authorized generic of Adzenys.

3. Forward Guidance and Outlook

• Revenue Expectations: Anticipated initial revenue from EXXUA in Q2 2026, with significant growth expected in Q3 and Q4 2026.
• Operating Expenses: Projected to be around $50 million for fiscal 2026, including $10 million for EXXUA launch investments.
• Breakeven Point: Estimated at approximately $17.3 million in net revenue per quarter, with cash breakeven at $16.6 million.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Overall revenue decreased compared to the prior year, primarily due to the absence of the one-time rebate benefit.
• Pediatric Portfolio Challenges: The pediatric segment is facing manufacturing delays and returns, leading to reduced revenue.
• FDA Regulatory Concerns: Ongoing monitoring of potential FDA actions regarding fluoride-containing products, though current revenue impact is minimal.
• Market Competition: The potential entry of generics into the ADHD market poses a risk, although management remains optimistic about maintaining market share.

5. Notable Q&A Insights

• Territory Realignment: Approximately one-third of sales territories have been adjusted to enhance coverage for EXXUA.
• Payer Engagement: Aytu is cautious about contracting with commercial payers to avoid jeopardizing government pricing; initial coverage expectations are optimistic.
• Target Prescriber Market: Initial outreach has received positive feedback, focusing on psychiatrists familiar with Aytu's products.
• Patient Profile: Targeting younger patients dissatisfied with current treatments due to side effects, aiming to position EXXUA as a viable alternative.

Overall, Aytu BioPharma is poised for a significant product launch with EXXUA, while navigating challenges in its existing portfolio and market competition. The management remains optimistic about future growth and profitability.